Reliance Life Sciences Pvt Ltd has received a licence from the Indian Institute of Technology Kanpur for a gene therapy method that has the potential to treat a variety of genetic eye ailments. Reliance Life Sciences will further develop the gene treatment technology from IIT Kanpur into a native product. The science of molecular medicine has recently seen the emergence of gene therapy employing viral vectors as a powerful tool.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
The patented technology was created by Jayandharan Giridhara Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), IIT Kanpur, to treat a genetic illness by altering an organism’s gene.
According to IIT Kanpur, this is the first instance in which a gene therapy-related technology has been created and given to a business in India. To meet unmet therapeutic requirements, Reliance Life Sciences is creating a number of different gene treatments. Also, the company is working on a variety of mRNA products and vaccines for both human and animal health.
Human gene therapy aims to change a gene’s expression or the biological characteristics of living cells for therapeutic purposes. Gene therapy is a method for treating or curing disease by changing a person’s DNA. Gene treatments can function in a variety of ways:
Products utilising gene therapy are being investigated for the treatment of diseases like cancer, genetic disorders, and infectious diseases.
You may also read this:
Ram Navami is a very special Hindu festival that celebrates the birth of Lord Ram.…
Seema Agrawal, a senior Indian Police Service (IPS) officer, has been appointed as the new…
Tamil Nadu has achieved the highest real economic growth rate in India for the year…
Samata Diwas is celebrated every year on April 5 to remember the birth anniversary of…
On April 5, 2025, Prime Minister Narendra Modi was awarded Sri Lanka’s highest civilian honour,…
On April 4, 2025, Bangladesh officially became the new Chair of BIMSTEC for the next…